Analytical Data
-
Gene name
COL7
- Application
-
Alternative Names
COL7；Collagen alpha-1(XV) chain
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9C9A9
-
Expression Region
1-392aa
-
AA Sequence
MVVDVESRTA SVTGEKMAAR GCDACMKRSR ASWYCPADDA FLCQSCDASI HSANHLAKRH ERVRLQSSSP TETADKTTSV WYEGFRRKAR TPRSKSCAFE KLLQIESNDP LVPELGGDED DGFFSFSSVE ETEESLNCCV PVFDPFSDML IDDINGFCLV PDEVNNTTTN GELGEVEKAI MDDEGFMGFV PLDMDLEDLT MDVESLLEEE QLCLGFKEPN DVGVIKEENK VGFEINCKDL KRVKDEDEEE EEAKCENGGS KDSDREASND KDRKTSLFLR LDYGAVISAW DNHGSPWKTG IKPECMLGGN TCLPHVVGGY EKLMSSDGSV TRQQGRDGGG SDGEREARVL RYKEKRRTRL FSKKIRYEVR KLNAEQRPRI KGRFVKRTSL LT
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Collagen type VII (COL7) is a crucial extracellular matrix protein primarily involved in anchoring fibrils that connect the epidermis to the dermis, playing a key role in skin integrity. Mutations in the COL7A1 gene, which encodes collagen type VII, lead to dystrophic epidermolysis bullosa (DEB), a severe genetic skin disorder characterized by fragility of the skin and mucous membranes resulting in blisters and wounds from minor mechanical stress. Given its pivotal role in skin structure and function, the study of COL7 recombinant proteins has gained considerable interest in recent years. Researchers aim to develop effective therapeutic interventions for DEB, including gene therapy, cell therapy, and protein replacement strategies. Recombinant COL7 proteins can be produced using various expression systems, offering potential for use in wound healing, tissue engineering, and restoring skin integrity in patients afflicted with DEB. In vitro studies and preclinical trials have shown promising results, indicating that these recombinant proteins may help to improve skin adhesion and reduce the incidence of blistering. Furthermore, understanding the structural and functional properties of COL7 is critical for designing effective treatments. As research advances, the use of COL7 recombinant proteins not only holds potential for DEB treatment but may also provide insights into broader applications in dermatology and regenerative medicine.
